Infliximab associated new-onset psoriasis
Adams, D.R.; Buckel, T.; Sceppa, J.A.
Journal of Drugs in Dermatology Jdd 5(2): 178-179
2006
ISSN/ISBN: 1545-9616 PMID: 16485887 Document Number: 9181
Infliximab infusion is not yet FDA-approved for psoriasis but has been reported to be very effective for plaque psoriasis. We report 2 patients without a history of psoriasis who after administration of infliximab for their inflammatory bowel disease experienced new onset, biopsy confirmed psoriasis.
Document emailed within 1 workday
Related Documents
Thurber, M.; Feasel, A.; Stroehlein, J.; Hymes, S.R. 2004: Pustular psoriasis induced by infliximab Journal of Drugs in Dermatology: Jdd 3(4): 439-440Pietrzak, A.; Chodorowska, G.; Jazienicka, I.; Junak-Bojarska, A.; Roliński, J. 2003: New development in the treatment of psoriasis--infliximab Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 58(1): 322-327
Krishnan, R.S.; Hsu, S. 2004: Serum sickness due to infliximab in a patient with psoriasis Journal of Drugs in Dermatology: Jdd 3(3): 305-308
Sri, J.C.; Tsai, C.L.; Deng, A.; Gaspari, A.A. 2007: Osteomyelitis occurring during infliximab treatment of severe psoriasis Journal of Drugs in Dermatology: Jdd 6(2): 207-210
Alabed, I.B.; Qushmaq, K.A.; Khan, M.A. 2010: Psoriasis induced by infliximab in a Saudi patient with ankylosing spondylitis Saudi Medical Journal 31(9): 1054-1056
Lewis, T.G.; Tuchinda, C.; Lim, H.W.; Wong, H.K. 2006: Life-threatening pustular and erythrodermic psoriasis responding to infliximab Journal of Drugs in Dermatology: Jdd 5(6): 546-548
Dilhuydy, M.S.; Vatan, R.; Etienne, G.; Longy-Boursier, M.; Mercié, P. 2005: Prolonged efficacy of infliximab for refractory adult-onset Still's disease Clinical and Experimental Rheumatology 23(1): 121-122
Weinberg, J.M.; Saini, R.; Tutrone, W.D. 2002: Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept Journal of Drugs in Dermatology: Jdd 1(3): 303-310
Kamili, Q.U.A.; Miner, A.; Hapa, A.; Menter, A. 2011: Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review Journal of Drugs in Dermatology: Jdd 10(5): 539-544
Krathen, R.A.; Berthelot, C.N.; Hsu, S. 2006: Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients Journal of Drugs in Dermatology: Jdd 5(3): 251-254
Tutrone, W.D.; Saini, R.; Weinberg, J.M. 2004: Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept Idrugs: the Investigational Drugs Journal 7(1): 45-49
Mahiques Santos, L.; Martínez Menchón, T.; Sánchez Carazo, Jé.Luis.; Fortea Baixauli, Jé.Miguel. 2005: Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy Medicina Clinica 125(4): 159
Weinberg, J.M.; Saini, R. 2003: Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept Cutis 71(1): 25-29
Zargari, O. 2005: Sustained effects of low dose infliximab in combination with methotrexate in the management of chronic recalcitrant psoriasis Dermatology Online Journal 11(3): 21
Menter, A.; Reich, K.; Gottlieb, A.B.; Bala, M.; Li, S.; Hsu, M-Chun.; Guzzo, C.; Diels, J.; Gelfand, J.M. 2008: Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations Journal of Drugs in Dermatology: Jdd 7(12): 1137-1146
Malaviya, R.; Sun, Y.; Tan, J.K.; Magliocco, M.; Gottlieb, A.B. 2006: Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis Journal of Drugs in Dermatology: Jdd 5(9): 890-893
Mattox, A.R.; Chappell, J.A.; Hurley, M.Y. 2013: New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris Journal of Drugs in Dermatology: Jdd 12(2): 217-219
Famenini, S.; Wu, J.J. 2013: Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases Journal of Drugs in Dermatology: Jdd 12(8): 939-943
Weinberg, J.M.; Bottino, C.J.; Lindholm, J.; Buchholz, R. 2005: Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept Journal of Drugs in Dermatology: Jdd 4(5): 544-555
Kalb, R.E.; Blauvelt, A.; Sofen, H.L.; Chevrier, M.; Amato, D.; Calabro, S.; Wang, J.; Schenkel, B.; Gottlieb, A.B. 2013: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial Journal of Drugs in Dermatology: Jdd 12(8): 874-880